Replies to post #681023 on NorthWest Biotherapeutics Inc (NWBO)

[skitahoe]

You may be right Tryn, but in the past a single trading halt seems normal, multiple trading halts caused by the same MM's that Posner is suing would be something the SEC really should take an interest in. I suspect the more the MM's screw with NWBO the more Posner will screw with them if it does go to a trial.

I frankly believe that whether it goes to trial or not will largely be decided by how many zeros are in the offering from the MM's. I'd also add that it wouldn't surprise me if some of the smaller MM's agreed to individual settlements to avoid what could be the outcome in court, and Posner and the company agreed to these settlements.

Frankly the winner of the election in November could even have an influence on the MM's decisions as they may believe the SEC under one President may be less vigilant than the other. At this time the SEC isn't involved, but the more attention the suit gets, the more likely that they could become involved. I suspect the company will take Posner's advice on whether or not settling with any one or all of the MM's together, of course this assumes an offer to settle.

The Chinese have an expression, "May you live in interesting times", we're certainly doing that.

Gary

[ilovetech]

I forgot the ticker, but saw it shared on ST, where a small biotech saw it's sp crater 48% upon receiving an FDA approval. I had to look it up at the time, and it was true. I didn't research beyond that, but it was something fairly recent, and not what I would have expected face value.

[Investor082]

I agree with you. None of the news has helped the stock so far including JAMA, TLD, MIA, etc. My sense is MHRA approval is unlikely to give us the valuation we deserve either unless there is some additional surprise coupled with it such as FDA or EU application submission guidance and/or couple hundred million in non dilutive funding from big pharma. A PR around one of this initiative will force the market makers to give us at least $4-5B market cap valuation in no time.